Rapid Response Innovation Awards (RRIA) program supports high-risk, high-reward projects with little-to-no existing preliminary data, but with potential to significantly impact our understanding of Parkinson’s disease (PD).
This program is well-suited for early exploratory studies that may open the field up to new targets or pathways that may ultimately feed the early drug development pipeline for a treatment of PD.
Funding
RRIA supports one-year grants up to US $75,000 total costs inclusive of both direct and indirect costs. No more than 10% of the direct costs may go to indirect costs.
Eligibility
Applications may be submitted by:
- U.S. and non-U.S. biotechnology/pharmaceutical companies or other for-profit entities, either publicly or privately held,
- U.S. and non-U.S. entities, public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.
As therapeutic programs may require many kinds of expertise, MJFF encourages industry and academic collaborations when appropriate. Post-doctoral fellows are eligible to apply as Principal Investigator (PI), but must collaborate with an Administrative PI who serves as the director of the laboratory in which the research will be conducted.